Should I Buy LTRN? LTRN 2026 Analysis

Should You Buy Lantern Pharma Inc (LTRN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

2.640

1 Day change

3.13%

52 Week Range

5.740

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price is in a clear breakdown below key support levels, momentum is still deteriorating, and there is no proprietary buy signal to override the setup.
For an impatient buyer, the near-term risk/reward is unfavorable: technicals point to continued weakness, while the next clear catalyst (earnings on 2026-02-11 pre-market) adds binary risk.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), consistent with a sustained downtrend.
Momentum: Bearish. MACD histogram is negative (-0.0429) and negatively expanding, signaling increasing downside momentum.
Oscillators: RSI(6) at ~22.5 indicates oversold conditions, but oversold is not a buy signal by itself while MACD/MA trend remain bearish.
Key levels: Current price (2.555) is below S2 (2.804), S1 (2.968), and pivot (3.233) — a technical “support failure.” Any bounce faces overhead resistance near ~2.80–2.97 first, then ~3.23.
Pattern-based short-term path: Similar-pattern read suggests elevated near-term downside risk (model implies a move toward ~2.20 is plausible in the next day), with a potential 1-month rebound skew (15.49%) that is not confirmed by current momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open interest put/call ratio is very low (0.13), indicating call-heavy open interest (calls 282 vs puts 37) — typically “risk-on/speculative” positioning.
Activity: Today’s options volume is 0 (illiquid/quiet tape), so the sentiment signal from volume is not actionable.
Volatility: 30D IV is extremely elevated (~748.67) with IV percentile ~99.6 / IV rank ~99.16, implying the options market is pricing extreme moves (often around catalysts) and making directional trades harder to time efficiently.
Takeaway: Options are priced for big movement, but with no volume today and very high IV, this is not a clean bullish confirmation; it reads more like speculative/earnings-style uncertainty than “smart money accumulation.”

Technical Summary

Sell

Buy

Positive Catalysts

- Upcoming earnings (2026-02-11 pre-market) can act as a near-term catalyst if results/updates surprise positively.
- Extremely oversold RSI can support a reflex bounce if selling pressure exhausts.
- Call-heavy open interest may reflect some speculative bullish expectations (though not confirmed by volume today).

Neutral/Negative Catalysts

- Strong bearish trend: breakdown below support (S2/S1/pivot) with bearish MA stack increases odds of continuation lower.
- Momentum still worsening: MACD histogram is negative and expanding.
- No supportive news flow in the last week to shift sentiment.
- Earnings event risk in a small-cap biotech profile: heightened uncertainty into the report.
- Options market pricing is extreme (IV ~748%): implies unstable price action and elevated gap risk around catalysts.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 0 (no meaningful revenue base).
Profitability: Net income declined to about -$4.18M (worse by ~7.29% YoY), and EPS fell to -0.39 (worse by ~7.14% YoY) — losses are widening rather than narrowing.
Overall: Financial trend does not show improving operating leverage; the equity is more dependent on event/catalyst outcomes than fundamental growth traction.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target changes were provided in the dataset, so a recent “Wall Street consensus shift” cannot be confirmed here.
Wall Street-style pros (typical for micro-cap biotech): potential upside is mostly catalyst-driven (trial/strategy updates), which can re-rate the stock quickly.
Wall Street-style cons: limited/zero revenue, ongoing losses, and high uncertainty make the stock highly sensitive to disappointments; current price action suggests the market is not positioning for sustained strength right now.

1 Analyst Rating

Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is 25 USD with a low forecast of 25 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.560

Low

Averages

High

Current: 2.560

Low

Averages

High

Lake Street

Chad Messer

Strong Buy

Initiates

$25

AI Analysis

2025-04-02

Reason

Lake Street

Chad Messer

Price Target

$25

AI Analysis

2025-04-02

Initiates

Strong Buy

Reason

Lake Street initiated coverage of Lantern Pharma with a Buy rating and $25 price target. Lantern's Response Algorithm for Drug Positioning and Rescue, or RADR, platform consists of a suite of AI modules designed to help advance cancer drug development, the analyst tells investors. Unlike many biotech AI platform companies, Lantern is monetizing RADR through advancement of its own pipeline of four clinical, plus additional preclinical, stage molecules, though they also engage in collaborations with partners, adds the analyst, who notes that lead clinical program LP-300 targets a unique set of lung cancer patients who never smoked.

LTRN Should I Buy

LTRN Should I Buy

Should You Buy Lantern Pharma Inc (LTRN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch